瑞宙生物完成数千万元A+轮融资，推进肺炎疫苗PCV24临床研发及上市

Group 1 - The core product of the company is the globally first innovative non-toxic dual protein carrier 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24), which has received clinical approval for all population indications [1][2] - The company has completed a Series A+ financing round of several tens of millions of yuan, with previous funding of 290 million yuan from Changchun High-tech and its subsidiary Baike Biotech [1] - The financing will primarily support the clinical research and market launch of PCV24 for adult and infant indications, with adult Phase II trials completed and Phase III trials upcoming [1][2] Group 2 - PCV24 is developed based on the epidemiological characteristics of pathogenic pneumococcal serotypes in China, aiming to improve protection coverage from 75% to over 90%, effectively addressing the growing issue of drug resistance [2] - The Phase II clinical trial results indicate that PCV24 shows excellent safety and immunogenicity in adults, achieving the expected outcomes across multiple immunogenicity evaluation indicators [2] - To establish a full industry chain layout, the company invested over 120 million yuan to create a high-standard GMP-level pilot research and production workshop in Shanghai, covering an area of 5,026 square meters [2][3]